These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17307356)

  • 1. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.
    Zhang T; Zhou JH; Shi LW; Zhu RX; Chen MB
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2156-60. PubMed ID: 17307356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators.
    Honório KM; Garratt RC; Polikarpov I; Andricopulo AD
    J Mol Graph Model; 2007 Mar; 25(6):921-7. PubMed ID: 17055759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
    Honorio KM; Garratt RC; Andricopulo AD
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3119-25. PubMed ID: 15893927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
    Pellicciari R; Costantino G; Camaioni E; Sadeghpour BM; Entrena A; Willson TM; Fiorucci S; Clerici C; Gioiello A
    J Med Chem; 2004 Aug; 47(18):4559-69. PubMed ID: 15317466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
    Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
    Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
    Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
    Vaidya M; Weigt M; Wiese M
    Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
    Pellicciari R; Sato H; Gioiello A; Costantino G; Macchiarulo A; Sadeghpour BM; Giorgi G; Schoonjans K; Auwerx J
    J Med Chem; 2007 Sep; 50(18):4265-8. PubMed ID: 17685603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
    Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
    J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
    Cariou B
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular field analysis and 3D-quantitative structure-activity relationship study (MFA 3D-QSAR) unveil novel features of bile acid recognition at TGR5.
    Macchiarulo A; Gioiello A; Thomas C; Massarotti A; Nuti R; Rosatelli E; Sabbatini P; Schoonjans K; Auwerx J; Pellicciari R
    J Chem Inf Model; 2008 Sep; 48(9):1792-801. PubMed ID: 18698841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR and molecular docking studies of selective agonists for the thyroid hormone receptor beta.
    Du J; Qin J; Liu H; Yao X
    J Mol Graph Model; 2008 Sep; 27(2):95-104. PubMed ID: 18436460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
    Martínez-Fernández P; Hierro L; Jara P; Alvarez L
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
    AbdulHameed MD; Hamza A; Liu J; Zhan CG
    J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5Alpha-bile alcohols function as farnesoid X receptor antagonists.
    Nishimaki-Mogami T; Kawahara Y; Tamehiro N; Yoshida T; Inoue K; Ohno Y; Nagao T; Une M
    Biochem Biophys Res Commun; 2006 Jan; 339(1):386-91. PubMed ID: 16300737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.